FDA Grants Priority Review to Sunvozertinib in EGFR+ NSCLC
The FDA has granted priority review to the new drug application (NDA) for sunvozertinib (DZD9008), an oral EGFR inhibitor, for the treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, …